Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

Rs12778366 single nucleotide polymorphism of Sirtuin 1 (SIRT1) and response to resveratrol supplementation in patients with type 2 diabetes mellitus.

Gambino R, Fanni G, Togliatto G, Ponzo V, Goitre I, Cassader M, Brizzi MF, Bo S.

Acta Diabetol. 2019 Aug;56(8):963-966. doi: 10.1007/s00592-019-01341-6. Epub 2019 Apr 12. No abstract available.

PMID:
30980188
2.

Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.

Musso G, Gambino R, Cassader M, Paschetta E.

BMJ. 2019 Apr 9;365:l1328. doi: 10.1136/bmj.l1328.

3.

Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation.

Musso G, Saba F, Cassader M, Paschetta E, De Michieli F, Pinach S, Framarin L, Berrutti M, Leone N, Parente R, Ayoubi Khajekini MT, Zarovska A, Gambino R.

Am J Gastroenterol. 2019 Apr;114(4):607-619. doi: 10.14309/ajg.0000000000000154.

PMID:
30920415
4.

Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial.

Bo S, Gambino R, Ponzo V, Cioffi I, Goitre I, Evangelista A, Ciccone G, Cassader M, Procopio M.

Nutr Diabetes. 2018 Sep 20;8(1):51. doi: 10.1038/s41387-018-0059-4.

5.

Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy.

Barutta F, Bellini S, Mastrocola R, Gambino R, Piscitelli F, di Marzo V, Corbetta B, Vemuri VK, Makriyannis A, Annaratone L, Bruno G, Gruden G.

Br J Pharmacol. 2018 Dec;175(23):4371-4385. doi: 10.1111/bph.14495. Epub 2018 Nov 6.

6.

Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM).

Ferrocino I, Ponzo V, Gambino R, Zarovska A, Leone F, Monzeglio C, Goitre I, Rosato R, Romano A, Grassi G, Broglio F, Cassader M, Cocolin L, Bo S.

Sci Rep. 2018 Aug 15;8(1):12216. doi: 10.1038/s41598-018-30735-9.

7.

Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis.

Musso G, Cassader M, Paschetta E, Gambino R.

Gastroenterology. 2018 Aug;155(2):282-302.e8. doi: 10.1053/j.gastro.2018.06.031. Epub 2018 Jun 12. Review.

PMID:
29906416
8.

Incidence of diabetes mellitus, cardiovascular outcomes and mortality after a 12-month lifestyle intervention: A 9-year follow-up.

Ponzo V, Gentile L, Gambino R, Rosato R, Cioffi I, Pellegrini N, Benso A, Broglio F, Cassader M, Bo S.

Diabetes Metab. 2018 Nov;44(5):449-451. doi: 10.1016/j.diabet.2018.04.008. Epub 2018 May 8. No abstract available.

PMID:
29773350
9.

Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution.

Musso G, Gambino R, Cassader M, Paschetta E, Sircana A.

Trends Pharmacol Sci. 2018 Apr;39(4):387-401. doi: 10.1016/j.tips.2018.01.003. Epub 2018 Feb 27. Review.

PMID:
29499974
10.

Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation.

Bo S, Togliatto G, Gambino R, Ponzo V, Lombardo G, Rosato R, Cassader M, Brizzi MF.

Acta Diabetol. 2018 Apr;55(4):331-340. doi: 10.1007/s00592-017-1097-4. Epub 2018 Jan 12.

11.

Impaired taste sensation in type 2 diabetic patients without chronic complications: a case-control study.

De Carli L, Gambino R, Lubrano C, Rosato R, Bongiovanni D, Lanfranco F, Broglio F, Ghigo E, Bo S.

J Endocrinol Invest. 2018 Jul;41(7):765-772. doi: 10.1007/s40618-017-0798-4. Epub 2017 Nov 28.

PMID:
29185232
12.

Letter by Musso et al Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".

Musso G, Cassader M, Gambino R.

Circulation. 2017 Oct 17;136(16):1563-1564. doi: 10.1161/CIRCULATIONAHA.117.028217. No abstract available.

PMID:
29038211
13.

Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance.

Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, Della Latta V, Ciociaro D, Abate ML, Gambino R, Cassader M, Bugianesi E, Gastaldelli A.

Hepatology. 2018 Jan;67(1):145-158. doi: 10.1002/hep.29465. Epub 2017 Nov 17.

PMID:
28802074
14.

MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat.

Musso G, Cassader M, De Michieli F, Paschetta E, Pinach S, Saba F, Bongiovanni D, Framarin L, Berrutti M, Leone N, Corvisieri S, Parente R, Molinaro F, Sircana A, Bo S, Gambino R.

Hum Mol Genet. 2017 May 1;26(9):1785. doi: 10.1093/hmg/ddx126. No abstract available.

PMID:
28398481
15.

Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy.

Barutta F, Grimaldi S, Gambino R, Vemuri K, Makriyannis A, Annaratone L, di Marzo V, Bruno G, Gruden G.

Nephrol Dial Transplant. 2017 Oct 1;32(10):1655-1665. doi: 10.1093/ndt/gfx010.

PMID:
28387811
16.

MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat.

Musso G, Cassader M, De Michieli F, Paschetta E, Pinach S, Saba F, Bongiovanni D, Framarin L, Berrutti M, Leone N, Corvisieri S, Parente R, Molinaro F, Sircana A, Bo S, Gambino R.

Hum Mol Genet. 2017 May 1;26(9):1747-1758. doi: 10.1093/hmg/ddw400. Erratum in: Hum Mol Genet. 2017 May 1;26(9):1785.

PMID:
28334911
17.

Targeting mitochondrial pyruvate carrier in nonalcoholic steatohepatitis: Growing evidence and future challenges.

Musso G, Gambino R.

Hepatology. 2018 May;67(5):2055. doi: 10.1002/hep.29164. Epub 2018 Feb 26. No abstract available.

PMID:
28317145
18.

The acute impact of the intake of four types of bread on satiety and blood concentrations of glucose, insulin, free fatty acids, triglyceride and acylated ghrelin. A randomized controlled cross-over trial.

Bo S, Seletto M, Choc A, Ponzo V, Lezo A, Demagistris A, Evangelista A, Ciccone G, Bertolino M, Cassader M, Gambino R.

Food Res Int. 2017 Feb;92:40-47. doi: 10.1016/j.foodres.2016.12.019. Epub 2016 Dec 27.

PMID:
28290296
19.

TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD.

Musso G, Cipolla U, Cassader M, Pinach S, Saba F, De Michieli F, Paschetta E, Bongiovanni D, Framarin L, Leone N, Berrutti M, Rosina F, Corvisieri S, Molinaro F, Sircana A, Gambino R.

J Lipid Res. 2017 Jun;58(6):1221-1229. doi: 10.1194/jlr.M075028. Epub 2017 Feb 27.

20.

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.

Musso G, Cassader M, Paschetta E, Gambino R.

JAMA Intern Med. 2017 May 1;177(5):633-640. doi: 10.1001/jamainternmed.2016.9607. Erratum in: JAMA Intern Med. 2017 May 1;177(5):747.

21.

Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial.

Bo S, Ponzo V, Evangelista A, Ciccone G, Goitre I, Saba F, Procopio M, Cassader M, Gambino R.

Acta Diabetol. 2017 May;54(5):499-507. doi: 10.1007/s00592-017-0977-y. Epub 2017 Feb 25.

PMID:
28238190
22.

Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges.

Musso G, Cassader M, Paschetta E, Gambino R.

Hepatology. 2017 Mar;65(3):1058-1061. doi: 10.1002/hep.28960. Epub 2017 Jan 31. No abstract available.

PMID:
27880988
23.

Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities.

Musso G, Cassader M, Cohney S, De Michieli F, Pinach S, Saba F, Gambino R.

Diabetes Care. 2016 Oct;39(10):1830-45. doi: 10.2337/dc15-1182. Review.

24.

New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease.

Musso G, De Michieli F, Bongiovanni D, Parente R, Framarin L, Leone N, Berrutti M, Gambino R, Cassader M, Cohney S, Paschetta E.

Clin Gastroenterol Hepatol. 2017 Jul;15(7):972-985. doi: 10.1016/j.cgh.2016.08.002. Epub 2016 Aug 10. Review.

PMID:
27521506
25.

Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial.

Bo S, Ponzo V, Ciccone G, Evangelista A, Saba F, Goitre I, Procopio M, Pagano GF, Cassader M, Gambino R.

Pharmacol Res. 2016 Sep;111:896-905. doi: 10.1016/j.phrs.2016.08.010. Epub 2016 Aug 9.

PMID:
27520400
26.

Peroxyl Radical Reactions in Water Solution: A Gym for Proton-Coupled Electron-Transfer Theories.

Amorati R, Baschieri A, Morroni G, Gambino R, Valgimigli L.

Chemistry. 2016 Jun 1;22(23):7924-34. doi: 10.1002/chem.201504492. Epub 2016 Apr 25.

PMID:
27111024
27.

Predictive role of the Mediterranean diet on mortality in individuals at low cardiovascular risk: a 12-year follow-up population-based cohort study.

Bo S, Ponzo V, Goitre I, Fadda M, Pezzana A, Beccuti G, Gambino R, Cassader M, Soldati L, Broglio F.

J Transl Med. 2016 Apr 12;14:91. doi: 10.1186/s12967-016-0851-7.

28.

Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load.

Gambino R, Bugianesi E, Rosso C, Mezzabotta L, Pinach S, Alemanno N, Saba F, Cassader M.

Int J Mol Sci. 2016 Mar 31;17(4):479. doi: 10.3390/ijms17040479.

29.

Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.

Musso G, Cassader M, Gambino R.

Nat Rev Drug Discov. 2016 Apr;15(4):249-74. doi: 10.1038/nrd.2015.3. Epub 2016 Jan 22. Review.

PMID:
26794269
30.

TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD.

Musso G, Cassader M, Paschetta E, Gambino R.

J Hepatol. 2016 Apr;64(4):979-81. doi: 10.1016/j.jhep.2015.11.036. Epub 2015 Dec 8. No abstract available.

PMID:
26673224
31.

Vacuum-Assisted Venous Drainage: A 2014 Safety Survey.

Gambino R, Searles B, Darling EM.

J Extra Corpor Technol. 2015 Sep;47(3):160-6.

32.

Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease.

Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A, Saba F, Vanni E, Younes R, Saponaro C, Buzzigoli E, Caviglia GP, Abate ML, Smedile A, Rizzetto M, Cassader M, Gastaldelli A, Bugianesi E.

Hepatology. 2016 Jan;63(1):107-16. doi: 10.1002/hep.28287. Epub 2015 Dec 8. Erratum in: Hepatology. 2017 Sep;66(3):1011.

PMID:
26473614
33.

Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease.

Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R.

Trends Mol Med. 2015 Oct;21(10):645-662. doi: 10.1016/j.molmed.2015.08.005. Review.

PMID:
26432021
34.

Trials of obeticholic acid for non-alcoholic steatohepatitis.

Musso G, Cassader M, Gambino R.

Lancet. 2015 Jul 4;386(9988):27. doi: 10.1016/S0140-6736(15)61198-9. No abstract available.

PMID:
26169860
35.

Dietary flavonoid intake and cardiovascular risk: a population-based cohort study.

Ponzo V, Goitre I, Fadda M, Gambino R, De Francesco A, Soldati L, Gentile L, Magistroni P, Cassader M, Bo S.

J Transl Med. 2015 Jul 8;13:218. doi: 10.1186/s12967-015-0573-2.

36.

Isoleucine-to-methionine substitution at residue 148 variant of PNPLA3 gene and metabolic outcomes in gestational diabetes.

Bo S, Gambino R, Menato G, Canil S, Ponzo V, Pinach S, Durazzo M, Ghigo E, Cassader M, Musso G.

Am J Clin Nutr. 2015 Feb;101(2):310-8. doi: 10.3945/ajcn.114.095125. Epub 2014 Dec 17.

PMID:
25646328
37.

PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease.

Musso G, Cassader M, Gambino R.

Hepatology. 2015 Aug;62(2):658-9. doi: 10.1002/hep.27643. Epub 2015 Jun 15. No abstract available.

PMID:
25482317
38.

Consuming more of daily caloric intake at dinner predisposes to obesity. A 6-year population-based prospective cohort study.

Bo S, Musso G, Beccuti G, Fadda M, Fedele D, Gambino R, Gentile L, Durazzo M, Ghigo E, Cassader M.

PLoS One. 2014 Sep 24;9(9):e108467. doi: 10.1371/journal.pone.0108467. eCollection 2014.

39.

Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.

Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Hafliðadóttir S, Björnsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Völzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M.

PLoS Med. 2014 Jul 22;11(7):e1001680. doi: 10.1371/journal.pmed.1001680. eCollection 2014 Jul. Review.

40.

High-normal blood pressure and impaired renal function. A prospective study in a population-based cohort.

Bo S, Gruden G, Charbonnier E, Martorana M, Gambino R, Cassader M, Gentile L, Cavallo-Perin P, Durazzo M.

Minerva Med. 2014 Jun;105(3):211-9.

PMID:
24988086
41.

Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice.

Barutta F, Grimaldi S, Franco I, Bellini S, Gambino R, Pinach S, Corbelli A, Bruno G, Rastaldi MP, Aveta T, Hirsch E, Di Marzo V, Gruden G.

Kidney Int. 2014 Nov;86(5):979-90. doi: 10.1038/ki.2014.165. Epub 2014 May 14.

42.

Simple lifestyle recommendations and the outcomes of gestational diabetes. A 2 × 2 factorial randomized trial.

Bo S, Rosato R, Ciccone G, Canil S, Gambino R, Poala CB, Leone F, Valla A, Grassi G, Ghigo E, Cassader M, Menato G.

Diabetes Obes Metab. 2014 Oct;16(10):1032-5. doi: 10.1111/dom.12289. Epub 2014 Apr 7.

43.

Gender specific medicine in liver diseases: a point of view.

Durazzo M, Belci P, Collo A, Prandi V, Pistone E, Martorana M, Gambino R, Bo S.

World J Gastroenterol. 2014 Mar 7;20(9):2127-35. doi: 10.3748/wjg.v20.i9.2127. Review.

44.

Stabilization of glucose in blood samples: out with the old, in with the new.

Gambino R, Bruns DE.

Clin Chem Lab Med. 2013 Oct;51(10):1883-5. doi: 10.1515/cclm-2013-0341. No abstract available.

PMID:
24072572
45.

Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism.

Musso G, Bo S, Cassader M, De Michieli F, Gambino R.

Am J Clin Nutr. 2013 Oct;98(4):895-906. doi: 10.3945/ajcn.113.063792. Epub 2013 Aug 28.

PMID:
23985808
46.

Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver.

Musso G, Paschetta E, Gambino R, Cassader M, Molinaro F.

Trends Mol Med. 2013 Sep;19(9):522-35. doi: 10.1016/j.molmed.2013.05.006. Epub 2013 Jun 28. Review.

47.

Diabetes-specific variables associated with quality of life changes in young diabetic people: the type 1 diabetes Registry of Turin (Italy).

Trento M, Panero F, Porta M, Gruden G, Barutta F, Cerutti F, Gambino R, Perotto M, Cavallo Perin P, Bruno G; Piedmont Study Group for Diabetes Epidemiology.

Nutr Metab Cardiovasc Dis. 2013 Oct;23(10):1031-6. doi: 10.1016/j.numecd.2013.01.004. Epub 2013 Mar 7.

48.

Variations of serum levels of adiponectin and resistin in chronic viral hepatitis.

Durazzo M, Belci P, Niro G, Collo A, Grisoglio E, Ambrogio V, Spandre M, Fontana R, Gambino R, Cassader M, Bo S.

J Endocrinol Invest. 2013 Sep;36(8):600-5. doi: 10.3275/8883. Epub 2013 Feb 27.

PMID:
23449040
49.

Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis.

Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R.

Obes Rev. 2013 May;14(5):417-31. doi: 10.1111/obr.12020. Epub 2013 Feb 6. Review.

50.

Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial.

Bo S, Ciccone G, Castiglione A, Gambino R, De Michieli F, Villois P, Durazzo M, Cavallo-Perin P, Cassader M.

Curr Med Chem. 2013;20(10):1323-31.

Supplemental Content

Loading ...
Support Center